anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Kidney disease is the most important predictor of death in patients with a Fontan circulation, yet its clinical and hemodynamic correlates have not been well established.
METHODS AND RESULTS: A total of 53 ambulatory patients with a Fontan circulation (median age, 16.2 years, 52.8% male patients) underwent advanced cardiovascular magnetic resonance assessment, including 4-dimensional flow imaging and computational fluid dynamics. Estimated glomerular filtration rate (eGFR) <90 mL/min per 1.73 m2 was observed in 20.8% and albumin-to-creatinine ratio >3 mg/mmol in 39.6%. The average eGFR decline rate was -1.83 mL/min per 1.73 m2 per year (95% CI, -2.67 to -0.99; P<0.001). Lower eGFR was associated with older age, larger body surface area at examination, longer time since Fontan procedure, and lower systemic ventricular ejection fraction. Higher albumin-to-creatinine ratio was associated with absence of fenestration at the Fontan operation, and older age and lower systemic ventricular ejection fraction at the assessment. Lower cross-sectional area of the Fontan conduit indexed to flow (r=0.32, P=0.038), higher inferior vena cava-conduit velocity mismatch factor (r=-0.35, P=0.022), higher kinetic energy indexed to flow in the total cavopulmonary connection (r=-0.59, P=0.005), and higher total cavopulmonary connection resistance (r=-0.42, P=0.005 at rest; r=-0.43, P=0.004 during exercise) were all associated with lower eGFR but not with albuminuria.
CONCLUSIONS: Kidney dysfunction and albuminuria are common among clinically well adolescents and young adults with a Fontan circulation. Advanced cardiovascular magnetic resonance-derived metrics indicative of declining Fontan hemodynamics are associated with eGFR and might serve as targets to improve kidney health. Albuminuria might be driven by other factors that need further investigation.
YH1 with one batch number was manufactured by Sun Ten Pharmaceutical Co., Ltd., a renowned manufacturer of concentrated herbal extract granules conforming to the standards of good manufacturing practices (GMP) in New Taipei City, Taiwan. YH1 contains Rhizoma Coptidis (50 %) and Shen-Ling-Bai-Zhu-San (SLBZS) (50 %). SLBZS consists of Radix Ginseng, Poria, Rhizoma Atractylodis macrocephalae, Semen Lablab album, Rhizoma Dioscoreae, Embryo Nelumbinis, Radix Platycodonis, Semen Coicis, Fructus Amomi, Fructus Jujubae, and Radix Glycyrrhizae at a 3:3:3:2.3:3:1.5:1.5:1.5:1.5:1.5:3 ratio. Subjects in the YH1 group orally ingested two packages of granules (3 g/package) three times daily with warm water after a meal for 12 consecutive weeks.
PCT No. PCT/US93/07791 Sec. 371 Date Apr. 18, 1995 Sec. 102(e) Date Apr. 18, 1995 PCT Filed Aug. 18, 1993 PCT Pub. No. WO94/05634 PCT Pub. Date Mar. 17, 1994There are disclosed certain novel compounds identified as benzo-fused lactams which promote the release of growth hormone in humans and animals. This property can be utilized to promote the growth of food animals to render the production of edible meat products more efficient, and in humans, to increase the stature of those afflicted with a lack of a normal secretion of natural growth hormone. Growth promoting compositions containing such benzo-fused lactams as the active ingredient therefore are also disclosed.
PURPOSE:To obtain a percutaneous absorption cataplasm slowly raising the concentration of a medicine in blood after attaching, suppressed in adverse effects such as nausea and vomiting, etc., capable of suitably using as a pharmaceutical agent for bronchial asthma and cerebro-vascular accidents to children and aged persons. CONSTITUTION:This percutaneous absorption cataplasm is obtained by forming a tacky agent layer consisting of (A) 100 pts.wt. of a tacky agent, preferably an acrylic or rubber-based tacky agent, (B) 1-30 pts.wt. of a percutaneous absorption promoter which is a long-chain fatty acid ester (preferably isopropyl myristate) consisting of a reactional product of a 10-18C long-chain fatty acid and a 1-5C alcohol or a 8-18C long-chain fatty acid ester (preferably undecylenic acid) and (C) 1-30 pts. wt. of 3-isobutylyl-2-isopropy1pyrrazolo[1,5-a]pyridine as a medicine on one face of a support. The cataplasm can provide an effective skin permeating amount in small area, because skin permeating property of the medicine is enhanced.
BACKGROUND AND PURPOSE: Non-O blood types are known to be associated with thromboembolic complications (TECs) in population-based studies. TECs are known drivers of morbidity and mortality in intracerebral hemorrhage (ICH) patients, yet the relationships of blood type on TECs in this patient population are unknown. We sought to explore the relationships between ABO blood type and TECs in ICH patients.
METHODS: Consecutive adult ICH patients enrolled into a prospective observational cohort study with available ABO blood type data were analyzed. Patients with cancer history, prior thromboembolism, and baseline laboratory evidence of coagulopathy were excluded. The primary exposure variable was blood type (non-O versus O). The primary outcome was composite TEC, defined as pulmonary embolism, deep venous thrombosis, ischemic stroke or myocardial infarction, during the hospital stay. Relationships between blood type, TECs and clinical outcomes were separately assessed using logistic regression models after adjusting for sex, ethnicity and ICH score.
RESULTS: Of 301 ICH patients included for analysis, 44% were non-O blood type. Non-O blood type was associated with higher admission GCS and lower ICH score on baseline comparisons. We identified TECs in 11.6% of our overall patient cohort. . Although TECs were identified in 9.9% of non-O blood type patients compared to 13.0% in O blood type patients, we did not identify a significant relationship of non-O blood type with TECs (adjusted OR=0.776, 95%CI: 0.348-1.733, p=0.537). The prevalence of specific TECs were also comparable in unadjusted and adjusted analyses between the two cohorts. In additional analyses, we identified that TECs were associated with poor 90-day mRS (adjusted OR=3.452, 95% CI: 1.001-11.903, p=0.050). We did not identify relationships between ABO blood type and poor 90-day mRS (adjusted OR=0.994, 95% CI:0.465-2.128, p=0.988).
CONCLUSIONS: We identified that TECs were associated with worse ICH outcomes. However, we did not identify relationships in ABO blood type and TECs. Further work is required to assess best diagnostic and prophylactic and treatment strategies for TECs to improve ICH outcomes.
PURPOSE: Biomechanical superiority of intramedullary nails over extramedullary implants has been proved for subtrochanteric fractures. Nevertheless, postoperative management of these patients has not changed, with high rates of protected weight-bearing after intramedullary nailing. The purpose of this study is to determine the mechanical complications of immediate postoperative full weigh-bearing for subtrochanteric femur fractures in elderly patients treated with a cephalomedullary nail.
METHODS: We performed a retrospective case series study from patients treated with a cephalomedullary nail for subtrochanteric fractures (AO/OTA 31A.3 and 32A-32C) over a nine-year period. Patients in the immediate full weight-bearing (IFWB) group received orders for immediate full weight bear as tolerated on postoperative 48 h. Patients in the non- or limited- weight-bearing (NLWB) group received orders not to full weight bear in the immediate postoperative.
RESULTS: There were five (2.7%) cases of implant failure including four cutouts and one nail breakage that needed a reoperation. Of them, one (2.2%) followed the NLWB protocol and four (2.9%) followed the IFWB protocol. Mean length of stay was 7.9 days (median 8, range 3-21) in the NLWB group and 10.7 days (median 8, range 2-60) in the IWBAT group. The NLWB group observed a 2.8-day shorter postoperative length of stay when compared to the IFWB, but the median remained equal.
CONCLUSION: This study suggests that geriatric patients with subtrochanteric fractures treated by intramedullary nailing and in which a good fracture reduction was achieved, may be able to tolerate immediate postoperative full weight-bearing, not increasing reoperation rates due to implant failure.
Treatment of virus infections of skin, eye and mucous membrane tissue susceptible to treatment with interferon (I) by topical appln. of synthetic or natural double-stranded RNA or a non-polynucleotide (II) as (I) inducer. The (I) inducer is used in conjunction with a water-soluble cellulose ther, polyvinyl alcohol, polyvinylpyrrolidone, carboxyvinyl polymer or polyethylene glycol. The release of (I) inducer is controlled, so that the optimum amt. is applied to the virus-infected tissue over a prolonged period. The (I) inducer is incorporated into a matrix of the polymer which is water-soluble and solid at or near body temp. Usually 0.0025-0.4 mg (I) inducer is used per 1 mg. of formulation.
PROBLEM TO BE SOLVED: To stabilize adhesion at the time of sweating, etc., and to reduce a pain, etc., at the time of releasing by setting the follow-up property, a water vapor transmission ratio, counter-bakelite adhesion respectively to a specific value. SOLUTION: As a supporter of an adhesive tape for sticking a skin, an extensible film whose extensible film follow-up property is not smaller than the 4.2 fold of film stress at the time of extending by 15% is used. In addition, its water vapor transmission ratio is not smaller than 500 g/m2 24 h and the counter bakelite adhesion is not larger than 1.5N/15 mm. As this extensible supporter, a polyurethane film, a polyurethane nonwoven fabric, etc., can be used. Its thickness is desirably about 40 to 200 μm in usual. For example, the copolymer of isononyeacrylate/methoxynonaethyleneglycol acrylate/nonaethylene glycol methacrylate, e.g. is used as the adhesive and a polyolefin type permeable film is formed as a supporter. Thus adhesion is stabilized.
NEW MATERIAL:A diyne compound of formula I (R1 is OH; R2 and R3 form oxy together; or R1 is H and R2 is OH; R3 is methoxy). EXAMPLE:A compound of formula II. USE:An carcinostatic agent. PREPARATION:Panax quinquefolium L. or a tissue cultured product is ground with a mixer and subsequently extracted with an organic solvent such as ethyl acetate. The extract solution is filtered and concentrated. The obtained only substance is subjected to adsorption chromatography. Two fractions obtained therefrom are further separated into four fractions by silica column chromatography, etc. A fraction A among the fractions is separated and purified by high performance liquid chromatography to provide the compound of formula I.
Placebo is administered intravenously every eight hours during 24h. This arm includes twosubjects (1 sentinel + 1 subject).
BACKGROUND: Despite the better prognosis of heart failure (HF) with improved ejection fraction (HFimpEF), remnant cardiovascular risks, including cardiovascular death, rehospitalization, and future deterioration of left ventricular (LV) systolic function, remain in HFimpEF. However, for HFimpEF patients, especially for those receiving guideline-directed medical therapy (GDMT), the recurrent LV systolic dysfunction and its risk factors is still unclear.
METHODS: A total of 1098 HF patients under HF follow-up management system were initially screened. Echocardiography was re-evaluated at 3-, 6-, and 12-month follow-up. After exclusion, a total of 203 HFimpEF patients on GDMT were enrolled in our final analysis. Cox regression analysis was conducted to select risk factors.
RESULTS: During the 1-year follow-up, a total of 28 (13.8%) patients had recurrent LV systolic dysfunction. The trajectory analysis of echocardiographic parameters illustrated that persistent decline of left ventricular ejection fraction (LVEF) and worsening LV remodeling was observed in patients with recurrent LV systolic dysfunction. Multivariable Cox regression analysis identified that ischemic cardiomyopathy, atrial fibrillation, higher left ventricular end-diastolic diameter index (LVEDDI), elevated serum potassium, and a lack of sodium-glucose co-transporter-2 inhibitors (SGLT2i) treatment were confirmed as independent risk factors for recurrent LV systolic dysfunction. Recurrent LV systolic dysfunction was associated with higher rehospitalization rate.
CONCLUSION: In our longitudinal cohort study, almost 14% HFimpEF receiving GDMT suffered recurrent LV systolic dysfunction. Ischemic cardiomyopathy, atrial fibrillation, higher LVEDDI, higher serum potassium, and a lack of SGLT2i therapy were tightly associated with recurrence of LV systolic dysfunction. Relapse of LV systolic dysfunction correlated with poor prognosis.
Increasing evidence indicate that neuroinflammation triggered by glial cells plays a significant role in epileptogenesis. To this effect, the overexpression of translocator protein 18 kDa (TSPO) in activated microglia and astrocytes has been identified as an inflammatory biomarker in epilepsy. It is now possible to quantify neuroinflammation using non-invasive positron emission tomography (PET) imaging of TSPO. With the advancement of radiotracers, TSPO PET has become an innovative tool in elucidating the "neuroinflammatory machinery" of drug-resistant epilepsy. Furthermore, TSPO PET has demonstrated potential in detecting MRI-negative epileptogenic zones (EZ) and provided an innovative perspective in epileptic medical treatment. This manuscript presents a comprehensive exploration of the neuroinflammatory mechanisms of epilepsy, alongside a thorough review of TSPO PET studies conducted in clinical and preclinical settings. The primary objective is to deepen our understanding of epilepsy progression and to establish TSPO PET as an effective monitoring tool for treatment efficacy.
PROBLEM TO BE SOLVED: To obtain the subject composition, free of smart sensation associated with an orally administered magnesium salt of organic acid, capable of manifesting excellent flavor, and useful for foods, medicines or the like for taking a sufficient quantity of magnesium by including an endothermic sweetener in a magnesium salt of organic acid. SOLUTION: This composition contains (A) a magnesium salt of organic acid, such as magnesium citrate, or fruit magnesium (e.g. a composition of fruit juice of high acidity, incorporated with magnesium oxide, magnesium hydroxide or the like to be kept at pH 8 or less) and (B) an endothermic sweetener (e.g. erythritol, xylitol or sorbitol). It is incorporated with, e.g. a flavor, powdered fruit juice, sweetener, stabilizer or grain flour, and used for foods in the form of powder, granule or tablet, bread, noodles or the like for magnesium taking.
Prior to the current amendment, no DLTs were observed at Dose Levels 1-5. Starting with the current protocol amendment, dosing decisions in monotherapy cohorts will utilize a 3+3 design for Dose Level 6. CRX100 infusion will occur every nine weeks (+/- 7 days). Subjects will receive up to a maximum of four infusions of CRX100 unless it is determined by the treating physician and the sponsor that it is in the best interest of the subjects to receive additional doses of CRX100 beyond four doses. A minimum of three DLT-evaluable subjects will be doses at Dose Level 6 and expanded to six subjects if determined necessary based on DLT incidence using the 3+3 design, and discussion with SRC and Sponsor.
The investigators have been working with children diagnosed with cerebral palsy (CP) for the past 10 years. The investigators have found that bone structure is markedly underdeveloped and bone strength is severely compromised in children with CP. Also, an increased fracture rate has been observed in the lower extremity bones of children with CP. There is evidence that Botox, which is used to treat spasticity in CP, can improve motor function; however the effect of Botox on human bone is unknown. There is also evidence that low magnitude vibration treatment can improve bone mass and bone structure. The overall goal of this current research study is to investigate the effect and mechanism of action of Botox and vibration on bone in children with CP. The investigators will also examine the effect of Botox on muscle volume.

A total of 36 participants will participate in this study. The investigators will assess bone structure and muscle volume using MRI. The investigators will assess bone mass using dual-energy X-ray absorptiometry (DXA).
Dolutegravir 50mg od given for 7 days with PK sampling at steady state, followed immediately by a further 3 days where Artemether-lumefantrine combination and Dolutegravir 50mg od are given together, again with PK sampling at steady state. Following a 21 day washout period, the subject will then receive Artemether-lumefantrine combination alone for 3 days, with PK sampling at steady state.
Maltodextrin powder is the placebo ingredient and this is encased in the same pale green capsules as the active ingredient. Participants, if in the placebo group, will consume x3 capsules of placebo per day for 28 days.
Mamas in Harmony is a 1 hour face to face intervention for mothers and their infants, delivered in groups of 10-12 mother-infant dyads, every week for 8 weeks. Mothers and infants also receive usual postnatal care from health and social care services.
A group of nerve fibers deep inside the ear helps people keep their balance. For some people, the motion of ships, airplanes, trains, automobiles, and buses increases the activity of these nerve fibers. This increased activity causes the dizziness, nausea, and vomiting of motion sickness. People may have one, some, or all of these symptoms.

Transderm Scōp contains the drug scopolamine, which helps reduce the activity of the nerve fibers in the inner ear. When a Transderm Scōp patch is placed on the skin behind one of the ears, scopolamine passes through the skin and into the bloodstream. One patch may be kept in place for 3 days if needed.

It has been suggested that Transderm Scōp, when used to reduce nausea and vomiting associated with surgical anesthesia or analgesia, acts on the same nerve fibers that are affected when the product is taken for motion sickness.
PURPOSE:To obtain a magnetic microsphere having variable particle diameter, narrow particle size distribution, excellent dispersibility and chemical stability, and high magnetic responsiveness by dispersing ferromagnetic fine particles hydrophobically treated in monomer, dispersively suspending the particles in aqueous solution and thermally polymerizing it. CONSTITUTION:Ferromagnetic fine particles preferably have approx. 150Angstrom  of diameter produced by a coprecipitating method. A hydrophobic treatment is performed by adsorbing an unsaturated fatty acid such as oleic acid to the surfaces of the fine particles or further by adsorbing a surfactant thereto. A polymerization initiator is not particularly limited if it is oil soluble radial polymerization initiator. Dispersant for dispersively suspending the monomer in the aqueous solution is preferably aqueous soluble polymer. The suspension is agitated in suspending step or polymerizing step, a low frequency ultrasonic wave is simultaneously irradiated to enhance the dispersing effect. Then, microspheres of 0.1 - several tens mum of diameter can be manufactured, and the size of produced microsphere is varied according to the frequency of the ultrasonic wave.
DOSAGE AND ADMINISTRATION:  Seborrheic dermatitis including seborrhea sicca  \-  Sodium Sulfacetamide 10% Wash: Wash affected areas twice daily (morning and evening), or as directed by your physician. Avoid contact with eyes or mucous membranes. Wet skin and liberally apply to areas to be cleansed, massage gently into skin working into a full lather, rinse thoroughly/pat dry and repeat after 10-20 seconds. Rinsing with plain water will remove any excess medication. Repeat application as described for eight to ten days. If skin dryness occurs it may be controlled by rinsing cleanser off sooner or using less frequently. Regular shampooing following Sodium Sulfacetamide 10% Wash is not necessary, but the hair should be shampooed at least once a week. As the condition subsides, the interval between applications may be lengthened. Applications once or twice weekly or every other week may prevent recurrence. Should the condition recur after stopping therapy, the application of Sodium Sulfacetamide 10% Wash should be reinitiated as at the beginning of treatment.

Secondary cutaneous bacterial infections \- Wet skin and liberally apply to areas to be cleansed, massage gently into skin for 10-20 seconds working into a full lather, rinse thoroughly and pat dry. Rinsing with plain water will remove any excess medication. Repeat application as described for eight to ten days. If skin dryness occurs it may be controlled by rinsing cleanser off sooner or using less often.
Objective: Autophagy elevation in endotoxemia plays a protective role by negatively regulating the pyroptosis of vascular endothelial cells, but the molecular mechanisms are still poorly understood. The present study aimed to identify the mechanism underlying autophagy and pyroptosis in endotoxemia. Methods: Bioinformatics analysis and whole-gene transcriptome sequencing prediction were used to identify the endotoxemia-related lncRNA-miRNA-mRNA axis of interest. Human umbilical vein endothelial cells (HUVECs) were activated by lipopolysaccharide (LPS) to mimic the inflammatory environment encountered in endotoxemia. Autophagy and pyroptosis of LPS-treated HUVECs were assessed in response to the knockdown of MALAT1 (metastasis-associated lung adenocarcinoma transcript 1)/miR-433-3p (miRNA-433-3p)/RPTOR (regulatory-associated protein of mTOR). The binding affinity of MALAT1, miR-433-3p, and RPTOR was detected by RNA pull-down and luciferase activity assays. The endothelial cell-specific RPTOR knockout mice were developed and rendered septic using LPS induction to verify the role of RPTOR in autophagy, pyroptosis, and inflammatory response in vivo . Results: The in vitro experiments indicated that LPS could stimulate HUVECs to highly express RPTOR, and its knockdown enhanced cellular autophagy and restricted pyroptosis to curb inflammatory responses. Mechanically, MALAT1 is competitively bound to miR-433-3p to release RPTOR expression, thereby promoting pyroptosis and aggravating endotoxemia. In vivo experiments further confirmed that the knockdown of RPTOR activated autophagy and curtailed pyroptosis in septic mice. Conclusion: MALAT1 is highly expressed in endotoxemia. MALAT1 promotes RPTOR expression by competitively absorbing miR-433-3p, inhibits LPS-activated HUVEC cell autophagy, promotes cell death, enhances LPS-induced inflammatory activation of vascular endothelial cells, and ultimately promotes the progression of endotoxemia.